NervGen Pharma Corp
NervGen Pharma Corp is a biotechnology company focused on the development of novel therapeutics for the treatment of neurological disorders, primarily through its lead product candidate, NG-217, for the treatment of multiple sclerosis.
Business. NervGen Pharma Corp (NGEN.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
6 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NervGen Pharma Corp (NGEN.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
NervGen Pharma Corp maintains a strong liquidity position, with cash and equivalents amounting to CAD 26.56 million, significantly exceeding its total liabilities of CAD 15.40 million, resulting in a current ratio of 1.78. The company's price-to-book ratio is 23.92, indicating a high valuation relative to its book value, while its debt-to-equity ratio is 0.01, reflecting minimal leverage.
The company's profitability metrics are negative, with a return on equity of -6.27% and a return on assets of -2.81%, both well below the industry median for biotechnology firms. Operating and net losses of CAD 6.00 million and CAD 7.83 million, respectively, underscore the company's ongoing financial challenges.
NervGen's revenue is not disclosed in the provided data, and the company does not report segment or geographic revenue breakdowns. As a pre-revenue biotechnology firm, its financial exposure is concentrated in research and development activities, with no disclosed geographic diversification.
The company's growth trajectory is speculative, with no revenue history provided. Analysts have assigned a mean price target of CAD 9.45, with a median of CAD 7.60, and all six recommendations are "buy" ratings. However, the absence of revenue and ongoing losses suggest that any growth is contingent on successful clinical trials and regulatory approvals.
Risk factors include the typical challenges of a pre-revenue biotechnology firm, such as clinical trial failure, regulatory hurdles, and competition. The company's dilution risk is currently low, with no immediate filing-based flags detected, and shares outstanding remain unchanged between basic and diluted shares.
Recent events include the ongoing development of NG-217, with no recent filings or transcripts indicating significant changes in the company's strategic direction. The company remains in the clinical development phase, with no commercial products to date.
- NervGen maintains a strong liquidity position with CAD 26.56 million in cash and equivalents.
- The company's profitability metrics are negative, with a return on equity of -6.27% and a return on assets of -2.81%.
- NervGen is a pre-revenue biotechnology firm with no disclosed geographic or segment revenue diversification.
- Analysts have assigned a mean price target of CAD 9.45, with all six recommendations being "buy" ratings.
- The company's growth is contingent on successful clinical trials and regulatory approvals, with no immediate dilution or liquidity risks detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- NervGen Pharma Corp Market data — financials · 2026-05-28
- NervGen Pharma Corp Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Mike KellyPresident, Chief Executive Officer, Director